This solution could benefit healthcare systems by providing greater levels of clarity to physicians
Healthcare company Roche Diagnostics has received CE mark approval for its Cobas Mass Spec solution, including the Cobas I 601 analyser and Ionify reagent pack of four assays for steroid hormones.
“The Cobas Mass Spec solution would make fully standardized clinical mass spectrometry more broadly available with the potential to improve patient care worldwide,” said Roche CEO Matt Sause.
“For example, in breast cancer patients receiving hormone therapy, mass spectrometry can help physicians detect subtle changes in therapeutic response earlier, allowing for timely adjustments to treatment.”
Following the launch, the Cobas Mass Spec solution will offer a menu of over 60 analytes for testing of steroid hormones, vitamin D metabolites, immunosuppressant drugs, therapeutic drug monitoring and drugs of abuse testing.
Roche’s automation technology enables high specificity, sensitivity and accuracy, while maintaining environmentally sustainable methods.
The solution will allow for timely decisions to be made regarding responses to disease progression and treatment.
The Cobas Mass Spec solution will be part of Roche’s established Cobas Pro integrated solutions which allows for full integration into clinical chemistry and immunochemistry testing as well as lab automation and IT.
